Zepbound maintenance dose after goal weight: what the labels say about long-term use
The short answer
For a Zepbound maintenance dose after goal weight, the label names 5 mg, 10 mg or 15 mg weekly. The Wegovy label names 2.4 mg weekly or the 25 mg daily tablet. In Zepbound's Study 4, body weight rose 14.0% over 52 weeks in patients switched to placebo, and fell a further 5.5% in those who kept taking Zepbound, according to the FDA label.
Key takeaways
- Zepbound maintenance doses for weight reduction: 5 mg, 10 mg or 15 mg weekly. Not 2.5 mg.
- Wegovy maintenance: 2.4 mg weekly injection, or 1.7 mg for adult weight reduction, or the 25 mg daily tablet.
- In Zepbound's Study 4, weight rose 14.0% over 52 weeks after patients switched to placebo.
- Missed 2 or more Wegovy injections in a row? The label restarts the step-up at a lower dose.
- On higher-strength LillyDirect Zepbound vials, refill within 45 days to keep the lower self-pay price.
On this page
- What is a maintenance dose?
- What are the maintenance doses, drug by drug?
- What happens when you stop? The trials on the labels
- Does the label expect diet and activity to continue?
- What interrupts maintenance: missed doses and restarts
- What does maintenance cost over a year?
- Questions to ask your prescriber about the long term
- Frequently asked questions
- Sources
“Maintenance” has a specific meaning on a GLP-1 label. It’s the dose you stay on once the step-up phase is over. For the weight-management products, it’s also half of what the medicine is approved for. Zepbound, Wegovy, Foundayo and Saxenda are each approved to reduce excess body weight and maintain weight reduction long term.
This guide covers three things: which doses each label treats as maintenance doses, what the labels’ own trials show about continuing versus stopping, and what long-term treatment costs. Every clinical figure comes from an FDA label on DailyMed. Trial results are averages from specific groups of study patients. They don’t predict what will happen to you, and nothing here is advice to start, stop or change a dose.
What is a maintenance dose?
It’s the dose where treatment is meant to settle. Every GLP-1 starts at a low dose and steps up. The Wegovy label gives the reason next to its dosing table: the step-up (escalation) is followed to reduce the risk of gastrointestinal adverse reactions, meaning stomach and gut side effects. The starting dose is there to help your body get used to the medicine. The maintenance dose is where the label intends treatment to settle.
The labels handle this in three different ways:
- A named set of maintenance doses (Zepbound, Wegovy).
- A single target dose (Saxenda).
- Escalation based on response, with no dose singled out as “the” maintenance dose (Foundayo, and the diabetes products).
What are the maintenance doses, drug by drug?
Zepbound
For weight reduction and long-term maintenance, the recommended maintenance dosage is 5 mg, 10 mg or 15 mg once weekly. For obstructive sleep apnea it’s 10 mg or 15 mg. The label says plainly that the 2.5 mg dose is for treatment initiation and is not approved as a maintenance dosage. In our dose records, 7.5 mg and 12.5 mg are escalation steps between the named maintenance doses.
Every one of those maintenance doses is written as once weekly. The label doesn’t describe spacing doses further apart, such as every other week, so ask your prescriber before you change how often you inject.
Wegovy
The usual recommended maintenance dosage of the injection is 2.4 mg once weekly. For weight reduction in adults, the label says the maintenance dosage is either 1.7 mg or 2.4 mg, with 2.4 mg the recommended one. Adults who tolerate 2.4 mg for at least 4 weeks, and for whom additional weight reduction is clinically indicated, may have the dose increased to a maximum of 7.2 mg once weekly.
For Wegovy tablets, the recommended maintenance dosage is 25 mg once daily. The label lets adults move between the two forms at maintenance. From the 2.4 mg injection, the 25 mg tablet starts one week after the last injection. From the 25 mg tablet, the 2.4 mg injection starts the day after the last tablet.
Saxenda
For adults, the recommended dosage is 3 mg daily, and the label says lower dosages are for titration only. Saxenda also has a rule the others in our records don’t. The label says to check the change in body weight 16 weeks after starting. If the adult patient hasn’t lost at least 4% of baseline body weight (their weight at the start), it says to discontinue, because it’s unlikely that the patient will achieve and sustain clinically meaningful weight loss with continued treatment.
Foundayo
The Foundayo label doesn’t name a maintenance dose in our records. After the required steps up to 5.5 mg once daily, the dose may go up to the next level (9 mg, 14.5 mg or 17.2 mg) after at least 30 days on the current dosage, based on treatment response and tolerability. The maximum is 17.2 mg once daily.
Ozempic, Rybelsus, Mounjaro and Trulicity
These labels are built around glycemic control (blood sugar control) in type 2 diabetes. So the question they ask is whether more blood sugar control is needed, not what weight you’ve reached.
- Ozempic injection: after 4 weeks at 0.25 mg, the dose is 0.5 mg weekly. If additional glycemic control is needed after at least 4 weeks, it may go up to 1 mg, and then to a maximum of 2 mg.
- Rybelsus: in our dose records, 7 mg is kept from day 61 if no additional glycemic control is needed, and 14 mg is used if it is.
- Mounjaro: our dose records note that the label doesn’t name specific maintenance doses. Steps above 5 mg are taken only if additional glycemic control is needed.
- Trulicity: the dose may go up for additional glycemic control, to a maximum recommended dosage of 4.5 mg once weekly.
The full schedules, with the minimum time at each step, are in the dosing guide and the titration schedule tool.
What happens when you stop? The trials on the labels
Two labels in our records, Zepbound and Wegovy, include a randomized withdrawal trial built to answer this. Everyone took the medicine first. Then some were randomly switched to placebo (a dummy treatment). The Saxenda label has a weight-maintenance trial with a different design.
Zepbound: Study 4
Study 4 was an 88-week randomized withdrawal trial. All patients took Zepbound, knowing what they were taking, for a 36-week lead-in. They were then randomly assigned to keep taking Zepbound or switch to placebo for 52 weeks.
- At the end of the 36-week lead-in, randomized patients had lost an average of 20.9% of their body weight.
- From week 36 to week 88, body weight rose 14.0% in the patients switched to placebo.
- Over the same period, it fell a further 5.5% in the patients who kept taking Zepbound, at their maximum tolerated dose of 10 mg or 15 mg.
- The difference between the groups at week 88 was -19.4%.
Wegovy: Study 5
In Study 5, the Wegovy injection dose was stepped up during a 20-week run-in. Patients who reached 2.4 mg weekly were then randomly assigned to keep taking Wegovy or switch to placebo for 48 weeks.
- From week 20 to week 68, body weight changed by +6.9% in the placebo group.
- It changed by -7.9% in the group that continued Wegovy.
- The difference was -14.8%.
The label adds a caution. Patients who stopped during titration, and those who didn’t reach 2.4 mg, couldn’t enter the randomized period. So the results may not reflect the experience of people in the general population who are first starting Wegovy.
Saxenda: Study 3 and the 160-week data
Study 3 was not a withdrawal trial. It enrolled adults who had first lost at least 5% of their body weight on a low-calorie diet, then compared Saxenda with placebo. Over the next 56 weeks, body weight changed by a further -4.9% on Saxenda and by +0.3% on placebo. The label cautions that because that earlier weight loss was a condition for taking part, the results may not reflect those expected in the general population.
The Saxenda label also reports longer follow-up from Study 1, in patients with abnormal glucose at randomization. At 56 weeks, 56% of Saxenda patients were known to have lost at least 5% of body weight, and 28% at 160 weeks. On placebo, the figures were 25% and 14%. The label presents these figures for descriptive purposes.
How to read these numbers
- You can’t compare them with each other. The trials differ in length, in how long people were treated before randomization, and in who was allowed in. A bigger figure on one label doesn’t show that one medicine is harder to stop than another.
- They’re averages. Some people in each group will have gained more and some less.
- They describe weight only, not blood sugar, blood pressure or other measures.
The page on stopping a GLP-1 covers what the labels say about stopping, and the rules for restarting after a gap.
Does the label expect diet and activity to continue?
Yes. The Zepbound label says to use it together with a reduced-calorie diet and increased physical activity, and the Foundayo label says the same. That instruction isn’t limited to the step-up months. The nutrition guide covers what our records hold on protein and eating while on treatment.
What interrupts maintenance: missed doses and restarts
Long-term treatment only works as intended if you take your doses on schedule. Some labels make you step back down after a gap:
- Wegovy injection: if 2 or more consecutive doses are missed, the label says to reinitiate dosage escalation at a lower dosage.
- Foundayo: if 7 or more consecutive doses are missed, reinitiate dosage escalation at a lower dosage.
- Saxenda: if more than 3 days have passed since the last dose, reinitiate at 0.6 mg daily and follow the escalation schedule again.
A restart means weeks back at lower doses before you return to your maintenance dose. A supply gap can cause this as easily as forgetting, so know when your next fill is due. The missed dose calculator applies the rule for your medicine.
What does maintenance cost over a year?
Maintenance is the long part of treatment, so the yearly figure matters more than the first month’s. Here’s a full year at one dose, self-pay through the manufacturer programs:
- Zepbound 15 mg vials, LillyDirect: $449 per fill, $5,837 for the year.
- Wegovy 2.4 mg pens, NovoCare: $349 per fill, $4,537 for the year.
- Wegovy 25 mg tablets, NovoCare: $299 per fill, $3,588 for the year.
- Foundayo 17.2 mg, LillyDirect: $299 per fill, $3,588 for the year.
Two things change these numbers in the maintenance phase.
The dose you settle on. Where a label allows a lower maintenance dose, the price can be lower too. A Zepbound 5 mg vial through LillyDirect is $399 per fill, against $449 at 15 mg. The dose is a clinical decision for your prescriber, not a budget one, but it’s fair to ask what each option costs.
Refill timing. LillyDirect’s self-pay price for the higher Zepbound vial strengths depends on refilling within 45 days. Miss that window and a 10 mg fill goes from $449 to $699. Over years of maintenance, that rule matters more than any introductory offer. The 45-day rule page explains it.
Zepbound vials come as a 28-day fill, which means 13 fills a year, not 12. That’s why a yearly figure can be higher than twelve times the per-fill price. For example, at 15 mg you pay $449 a fill, 13 times a year, which comes to $5,837. The cost calculator works out a year for your medicine, dose and way of paying, and the GLP-1 cost guide compares the routes. If you have Medicare, long-term coverage for weight management runs through the GLP-1 Bridge, which CMS has set to end on December 31, 2027.
Questions to ask your prescriber about the long term
- Which dose is my maintenance dose, and does the label allow a lower one for me?
- How will we judge whether the medicine is working well enough to continue?
- If I want to stop, or have to for cost, pregnancy or surgery, how should that be done?
- If I miss doses, at what point do I need to restart at a lower dose?
- What will a year at this dose cost me through my plan, and what’s the self-pay fallback?
Frequently asked questions
What is the maintenance dose of Zepbound?
For weight reduction and long-term maintenance, the Zepbound label's recommended maintenance dosage is 5 mg, 10 mg or 15 mg injected once weekly. For obstructive sleep apnea it's 10 mg or 15 mg. The 2.5 mg dose is for starting treatment (treatment initiation) and is not approved as a maintenance dosage.
What is the maintenance dose of Wegovy?
The usual recommended maintenance dosage of Wegovy injection is 2.4 mg once weekly. For weight reduction in adults, the label says the maintenance dosage is either 1.7 mg or 2.4 mg, with 2.4 mg recommended. For Wegovy tablets, the recommended maintenance dosage is 25 mg once daily.
What happens when you stop Zepbound?
The label's withdrawal trial, Study 4, gives one measured answer. After 36 weeks on Zepbound, patients were randomly assigned to keep taking it or switch to placebo for 52 weeks. Body weight rose 14.0% in the placebo group and fell a further 5.5% in the group that stayed on Zepbound. Results vary from person to person, and stopping is a decision to make with your prescriber.
Do you gain weight back after stopping Wegovy?
In the label's Study 5, patients who had reached 2.4 mg after a 20-week run-in were randomly assigned to keep taking Wegovy or switch to placebo for 48 weeks. Body weight changed by +6.9% in the placebo group and -7.9% in the group that continued. The label cautions that the results may not reflect people first starting Wegovy.
Do you have to stay on a GLP-1 forever?
No label in our records sets a time limit or requires lifelong use. The weight-management products are approved to reduce excess body weight and maintain weight reduction long term. The withdrawal trials on the Zepbound and Wegovy labels show weight rising after a switch to placebo. How long to continue is a decision for you and your prescriber.
Can you stay on a lower dose for maintenance?
Some labels allow it. Zepbound's label lists 5 mg as a maintenance dose for weight reduction, alongside 10 mg and 15 mg. Wegovy's lists 1.7 mg as an alternative to the recommended 2.4 mg for weight reduction in adults. Saxenda's label says doses below 3 mg are for titration only in adults. Your prescriber chooses the dose.
Is there a maintenance dose of Ozempic or Mounjaro?
The Ozempic and Mounjaro labels are written around blood sugar control, not weight. In our dose records, Ozempic 0.5 mg is the first maintenance dosage, and the dose goes up only if additional glycemic control is needed, to a maximum of 2 mg weekly. The Mounjaro label doesn't name specific maintenance doses.
How much does a year of maintenance cost?
Here's a full year at one dose, self-pay: Zepbound 15 mg vials through LillyDirect cost $5,837, Wegovy 2.4 mg pens through NovoCare $4,537, Wegovy 25 mg tablets $3,588 and Foundayo 17.2 mg $3,588. If you have insurance that covers your medicine, these figures change.
Sources (32)
- 1.Wegovy prescribing information, section 2 (dosage)
“The usual recommended maintenance dosage of WEGOVY injection is 2.4 mg once weekly.”
- 2.Wegovy prescribing information, section 2 (dosage, weight reduction in adults)
“Table 1: Dosage Escalation, Weeks 13 through 16, 1.7 mg. The maintenance dosage of WEGOVY for weight reduction in adults is either 1.7 mg or 2.4 mg (recommended) injected subcutaneously once weekly.”
- 3.Wegovy prescribing information, section 2 (7.2 mg dosage)
“For patients who tolerate the 2.4 mg dosage for at least 4 weeks and additional weight reduction is clinically indicated, the dosage may be increased to a maximum dosage of 7.2 mg subcutaneously once weekly.”
- 4.Wegovy prescribing information, section 2 (tablets)
“The recommended maintenance dosage of WEGOVY tablets is 25 mg orally once daily.”
- 5.Zepbound prescribing information, section 2 (maintenance dosage by indication)
“Weight Reduction and Long-Term Maintenance: The recommended maintenance dosage is 5 mg, 10 mg, or 15 mg, injected subcutaneously once weekly. OSA: The recommended maintenance dosage is 10 mg or 15 mg injected subcutaneously once weekly.”
- 6.Saxenda prescribing information, section 2 (dosage)
“For adults, the recommended dosage of SAXENDA is 3 mg daily, lower dosages are for titration only.”
- 7.Foundayo prescribing information, section 2 (dosage)
“The dosage may be increased to the next dosage level (9 mg, 14.5 mg, or 17.2 mg once daily) after at least 30 days on the current dosage, based on treatment response and tolerability.”
- 8.Ozempic prescribing information, section 2 (dosage)
“If additional glycemic control is needed after at least 4 weeks on the: 0.5 mg dosage, the dosage may be increased to 1 mg once weekly.”
- 9.FDA label (DailyMed): Zepbound prescribing information, section 2.2
“The recommended maintenance dosage is 5 mg, 10 mg, or 15 mg, injected subcutaneously once weekly.”
- 10.FDA label (DailyMed): Zepbound prescribing information, section 2.1
“The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage.”
- 11.FDA label (DailyMed): Zepbound prescribing information, section 14.1
“Study 4 (NCT04660643) was an 88-week randomized withdrawal trial in which all patients received open-label ZEPBOUND during a 36-week lead-in period, followed by randomization to either continue ZEPBOUND or switch to placebo for 52 weeks.”
- 12.FDA label (DailyMed): Zepbound prescribing information, section 14.1
“After open-label ZEPBOUND treatment, randomized patients (n=670) had an average body weight loss of 20.9% (Week 0 to Week 36).”
- 13.FDA label (DailyMed): Zepbound prescribing information, section 14.1, Table 6
“Table 6: Changes in Body Weight After 36-Week Open-Label Treatment Followed by Randomized Withdrawal (Study 4) in Patients with Obesity or Overweight. % change from Week 36 at Week 88: Placebo N=335: 14.0; ZEPBOUND (MTD 10 mg or 15 mg) N=335: -5.5”
- 14.FDA label (DailyMed): Zepbound prescribing information, section 14.1, Table 6
“Table 6: Changes in Body Weight After 36-Week Open-Label Treatment Followed by Randomized Withdrawal (Study 4) in Patients with Obesity or Overweight. % difference from placebo at Week 88 (95% CI): ZEPBOUND (MTD 10 mg or 15 mg) N=335: -19.4 (-21.2, -17.7)”
- 15.FDA label (DailyMed): Wegovy prescribing information, section 14.2
“In Study 5 (NCT#03548987), WEGOVY injection was escalated during a 20-week run-in period, and patients who reached a WEGOVY 2.4 mg subcutaneous injection weekly dosage after the run-in period were randomized to either continued treatment with WEGOVY injection or placebo for 48 weeks.”
- 16.FDA label (DailyMed): Wegovy prescribing information, section 14.2, Table 9
“From randomization (week 20) to Week 68, treatment with WEGOVY injection resulted in a statistically significant reduction in body weight compared with placebo (Table 9).”
- 17.FDA label (DailyMed): Wegovy prescribing information, section 14.2
“Because patients who discontinued WEGOVY injection during titration and those who did not reach the 2.4 mg weekly dose were not eligible for the randomized-treatment period, the results may not reflect the experience of patients in the general population who are first starting WEGOVY injection.”
- 18.FDA label (DailyMed): Wegovy prescribing information, section 2.5
“One week after discontinuing WEGOVY 2.4 mg injection, initiate 25 mg of WEGOVY tablets orally once daily.”
- 19.FDA label (DailyMed): Wegovy prescribing information, section 2.5
“The day after discontinuing WEGOVY tablets 25 mg once daily, initiate WEGOVY 2.4 mg subcutaneous injection once weekly.”
- 20.FDA label (DailyMed): Saxenda prescribing information, section 14.1, Table 4
“In Study 3, statistically significantly more patients randomized to SAXENDA than placebo had not gained more than 0.5% of body weight from randomization to Week 56.”
- 21.FDA label (DailyMed): Saxenda prescribing information, section 14.1
“Because losing at least 5% of fasting body weight through lifestyle intervention during the 4- to 12-week run-in was a condition for their continued participation in the randomized treatment period, the results may not reflect those expected in the general population.”
- 22.FDA label (DailyMed): Saxenda prescribing information, section 14.1, Table 5
“The numbers and percentages of patients known to have lost greater than or equal to 5% body weight at Week 56 and/or Week 160 in Study 1 (patients with abnormal glucose at randomization only) are summarized in Table 5 for descriptive purposes.”
- 23.FDA label (DailyMed): Saxenda prescribing information, section 2.2
“Evaluate the change in body weight 16 weeks after initiating SAXENDA and discontinue SAXENDA if the patient has not lost at least 4% of baseline body weight, since it is unlikely that the patient will achieve and sustain clinically meaningful weight loss with continued treatment.”
- 24.FDA label (DailyMed): Saxenda prescribing information, section 2.1
“If more than 3 days have elapsed since the last SAXENDA dosage, reinitiate SAXENDA at 0.6 mg daily and follow the dosage escalation schedule in Table 1, to reduce the risk of gastrointestinal adverse reactions associated with reinitiation of treatment.”
- 25.FDA label (DailyMed): Foundayo prescribing information, section 2.1
“The maximum dosage of FOUNDAYO is 17.2 mg once daily.”
- 26.FDA label (DailyMed): Foundayo prescribing information, section 2.3
“If 7 or more consecutive doses are missed, reinitiate dosage escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions [see Dosage and Administration (2.1), Warnings and Precautions (5.3), Adverse Reactions (6)].”
- 27.FDA label (DailyMed): Foundayo Medication Guide (in the prescribing information)
“Use FOUNDAYO with a reduced-calorie diet and increased physical activity.”
- 28.FDA label (DailyMed): Zepbound prescribing information, section 2.4
“Administer ZEPBOUND in combination with a reduced-calorie diet and increased physical activity.”
- 29.FDA label (DailyMed): Trulicity prescribing information, section 2.1
“The maximum recommended dosage is 4.5 mg injected subcutaneously once weekly.”
- 30.
- 31.
- 32.
Related pages
- Stopping Zepbound, Wegovy or another GLP-1: what the labels say
- GLP-1 dosing chart: how the eight medicines start, step up and settle
- GLP-1 cost: how much each medicine costs a month
- What is Zepbound? Uses, cost, doses and side effects
- What is Wegovy? Uses, doses, pill and pen, and cost
- Saxenda (liraglutide): uses, doses, cost and how to take it
